You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
|
|---|---|
| Published in |
Frontiers in oncology, April 2018
|
| DOI | 10.3389/fonc.2018.00088 |
| Pubmed ID | |
| Authors |
J. Remon, Benjamin Besse |
| Abstract |
Brain metastases (BM) are common in non-small cell lung cancer patients including in molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They are associated with a reduced quality of life, and are commonly the first site of progression for patients receiving tyrosine kinase inhibitors (TKIs). In this review, we summarize incidence of BM and intracranial efficacy with TKI agents according to oncogene driver mutations, focusing on important clinical issues, notably optimal first-line treatment in oncogene-addicted lung tumors with upfront BM (local therapies followed by TKI vs. TKI monotherapy). We also discuss the potential role of newly emerging late-generation TKIs as new standard treatment in oncogene-addicted lung cancer tumors compared with sequential strategies. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 33% |
| Switzerland | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 16% |
| Other | 9 | 13% |
| Student > Master | 8 | 11% |
| Student > Postgraduate | 7 | 10% |
| Student > Bachelor | 5 | 7% |
| Other | 12 | 17% |
| Unknown | 18 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 36% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Nursing and Health Professions | 2 | 3% |
| Unspecified | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 28 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2021.
All research outputs
#17,292,294
of 25,382,440 outputs
Outputs from Frontiers in oncology
#8,031
of 22,428 outputs
Outputs of similar age
#221,421
of 343,278 outputs
Outputs of similar age from Frontiers in oncology
#74
of 133 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,278 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 133 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.